AI Article Synopsis
- The study aimed to investigate how faecal haemoglobin (f-Hb) levels change between rounds of colorectal cancer (CRC) screening and how they relate to colonoscopy results in Scotland's bowel screening program.
- Researchers compared f-Hb concentrations and outcomes from the first and second rounds among participants with different initial test results, including negative and positive FIT results.
- Findings indicated that f-Hb levels varied depending on the test results from the first round, and having a negative colonoscopy does not completely rule out the possibility of significant pathology being found in subsequent screenings.
Article Abstract
Objective: How faecal haemoglobin concentrations (f-Hb) vary from one round to the next in a colorectal cancer (CRC) screening programme, and relate to colonoscopy findings, are unknown. Our aim was to use data from the first two rounds of the faecal immunochemical test (FIT) based Scottish Bowel Screening Programme (SBoSP) to explore these issues.
Methods: Faecal haemoglobin concentration (f-Hb) percentiles in the second round were compared with those in the first when the first round yielded a negative FIT result (<80 µg Hb/g faeces), a positive FIT but no colonoscopy, CRC, all adenoma, and a negative colonoscopy. In addition, the outcomes in the first and second rounds were compared.
Results: The profiles of f-Hb in the first and second rounds differed in (a) those who had had a negative FIT result in the first round and (b) those in whom neoplastic pathology had been found. In contrast, the pattern of difference between profiles in those who had had a negative colonoscopy was very similar to that in those in whom an adenoma had been found. In addition, the risk of CRC being diagnosed in the second round after a negative colonoscopy in the first was 3.0%, not very different to that after a negative test result (4.9%).
Conclusions: Adenomas may be rarely the cause of a positive FIT result. An alternative explanation as to why these are detected using FIT is required. In addition, a negative colonoscopy for a positive FIT result does not rule out the finding of significant neoplastic pathology in the next round.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574424 | PMC |
| http://dx.doi.org/10.1177/09691413221110012 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Attenuation of Experimental Cholesterol Gallstone Formation by Manganese Chloride in Mice: Role of NF-κβ Pathways.
Biol Trace Elem Res
December 2024
University of Ibadan, Ibadan, Nigeria.
Manganese (Mn), a trace element, has been documented to exert an important role in the metabolism of cholesterol. Cholesterol gallstone (CG) pathogenesis is directly linked to biliary cholesterol imbalance which could be due to diabetes complications or mismanagement. NF-κβ pathway, an inflammatory regulator, has been implicated in metabolic disease especially in the context of diabetes and gallstone formation.
View Article and Find Full Text PDF28-Day Repeated Dose Toxicity and Toxicokinetics Study on Dihydroartemisinin (DHA) in SD Rats.
J Appl Toxicol
December 2024
School of Pharmaceutical Sciences, Nanjing Tech University, Nanjing, China.
Dihydroartemisinin (DHA) is an effective antimalarial drug with potential antitumor efficacy, yet toxicological information is limited. The present study was designed to evaluate the potential toxicity of oral DHA. DHA was administered orally by gavage to SD rats at doses of 0, 25, 50, and 75/60 mg/kg b.
View Article and Find Full Text PDFInterval cancer risk after the upper age limit of screening has been reached: Informing risk stratification in FIT-based colorectal cancer screening.
Int J Cancer
December 2024
Department of Public Health, Erasmus MC University Medical Centre, Rotterdam, The Netherlands.
Upper age limits are currently fixed for all fecal immunochemical test (FIT)-based colorectal cancer (CRC) screening programs. A risk-stratified upper age limit may be beneficial. Therefore, we assessed differences in interval CRC risk among individuals who had reached the upper age limit of screening (75 years).
View Article and Find Full Text PDFCommunity pharmacist-led point-of-care colorectal cancer screening program: Early detection of colorectal cancer in high-risk patients.
Res Social Adm Pharm
December 2024
Department of Clinical Pharmacy & Pharmacotherapeutics, Dubai Pharmacy College for Girls, AlMuhaisanah 1, Al mizhar, Dubai, United Arab Emirates. Electronic address:
Background: The prevalence of colorectal cancer (CRC) is on the rise among the younger population, with an anticipated increase in new cases for individuals aged 20-49 years by 2030. The accessibility of community pharmacists and their strong community connections present unique opportunities to enhance patient engagement in a population-based CRC screening program.
Objectives: This study seeks to assess the effectiveness of a community pharmacist-led point-of-care CRC screening program utilizing fecal immunochemical test (FIT) kits to identify CRC prevalence in high-risk individuals.
Faecal immunochemical tests for patients with symptoms suggestive of colorectal cancer: An updated systematic review and multiple-threshold meta-analysis of diagnostic test accuracy studies.
Colorectal Dis
December 2024
SCHARR, University of Sheffield, Sheffield, UK.
Aim: Extending faecal immunochemical tests for haemoglobin (FIT) to all primary care patients with symptoms suggestive of colorectal cancer (CRC) could identify people who are likely to benefit from colonoscopy and facilitate earlier treatment. The aim of this work was to investigate the diagnostic accuracy of FIT across different analysers at different thresholds, as a single test or in duplicate (dual FIT).
Method: This systematic review and meta-analysis searched 10 sources (December 2022).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!